Search
for
Sort by
Research
930-960 / 1000+ results
research Luncheon Symposium (LS) : Update on the efficacy and safety of dutasteride in the management of androgenetic alopecia
Dutasteride is effective and safe for treating common hair loss, and it's more potent than finasteride, leading to better hair growth and thickness.
research 1343 Efficacy of asymmetric siRNA targeting androgen receptor for the treatment of androgenetic alopecia
cp-asiAR may effectively treat hair loss by targeting androgen receptors.
research PD05-10 COMPARATIVE EFFECTS OF FINASTERIDE AND DUTASTERIDE ON SEMEN PARAMETERS IN YOUNG MEN WITH ANDROGENIC ALOPECIA: A RANDOMIZED CONTROLLED STUDY
Finasteride and dutasteride reduce semen quality, with dutasteride having a stronger negative effect.
research Clinical applications of antiandrogens
Antiandrogens are effective for conditions like prostate cancer and skin issues, but more research is needed to confirm their benefits and minimize side effects.
research Frontal fibrosing alopecia after antiandrogen hormonal therapy in a male patient
A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.
research Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1<i>H</i>-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
A new compound shows promise as a topical treatment for hair loss.
research Case report: NUDT15 polymorphism and severe azathioprine-induced myelosuppression in a young Chinese female with systematic lupus erythematosus: a case analysis and literature review
Genetic screening for NUDT15 polymorphisms is crucial for patients taking azathioprine, especially in Asians.
research Intralesional Methotrexate Is Comparable to Triamicinolone Acetonide and Superior to Vitamin D3 in the Treatment of Alopecia Areata
Intralesional methotrexate and triamcinolone acetonide are more effective than Vitamin D3 for treating alopecia areata.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Old drug new indication: Tofacitinib for a new crop of hair?
Tofacitinib might be used to treat hair loss.
research 200 Uncommon finasteride side effects in male androgenic alopecia
research Use of lufenuron for treating fungal infections of dogs and cats: 297 cases (1997–1999)
Lufenuron effectively and quickly treats fungal infections in dogs and cats without side effects.
research Incidence of alopecia from endocrine therapies in cancer
Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
research Intralesional Injection of Triamcinolone Acetonide, Methotrexate and Vitamin D in Treatment of Alopecia Areata: A Narrative Review
Methotrexate and vitamin D3 are potentially more effective and safer than triamcinolone for treating localized alopecia areata.
research Genetic variations associated with response to dutasteride in the treatment of male subjects with androgenetic alopecia
Genetic variations affect dutasteride treatment response for male pattern hair loss.
research Differential association between cumulative dose of 5α-reductase inhibitors and mortality
Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
research PPAR-γ Agonists and Their Role in Primary Cicatricial Alopecia
PPAR-γ helps control skin oil glands and inflammation, and its disruption can cause hair loss diseases.
research Treatment of insulin resistance with tirzepatide leading to improvement of hair loss
Tirzepatide may improve hair loss by reducing insulin resistance.
research Cutaneous hyperandrogenism: role of antiandrogen therapy in acne, hirsutism, and androgenetic alopecia.
research ADVERSE EFFECTS OF RITLECITINIB IN ADULTS AND ADOLESCENTS WITH ALOPECIA AREATA: A LITERATURE REVIEW
Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
research Medicaid coverage of Janus kinase inhibitors for alopecia areata treatment
Medicaid coverage for alopecia areata treatments is inconsistent and often limited.
research اثر تستوسترون اگزوژن و داروی Finasteride بر بی دردی ناشی از مورفین در موش های سوری نر با استفاده از تست فرمالین
Testosterone reduces, while finasteride enhances, morphine's pain relief.
research P123 : Oral Janus kinase inhibitors for the treatment of alopecia areata: a systematic review and metaanalysis
Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.
research 307 Dermatologic toxicities associated with chronic gamma-secretase inhibitor treatment for desmoid tumor
Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.
research Adverse Side Effects of 5α‐Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients
Some patients taking finasteride or dutasteride may have ongoing sexual problems and depression even after stopping the medication.
research Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review
GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
research Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study
Men taking dutasteride or finasteride have a slightly higher risk of developing type 2 diabetes.
research Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis
Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.
research A Review on Steroidal 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia
New treatments for enlarged prostate are being developed, some of which may be more effective than current medications.